Cleveland Clinic Rheumatology

Cleveland Clinic offers expert diagnosis, treatment and rehabilitation for bone, joint or connective tissue disorders and rheumatic and immunologic diseases.

 

Cleveland Clinic Rheumatology
Avatar

Safety of Biologics and JAK Inhibitors (Mycobacterial Infections)

By Cleveland Clinic Rheumatology FEATURING Kevin Winthrop
By Cleveland Clinic Rheumatology FEATURING Kevin Winthrop
273 views
April 18, 2023
0 Comments
Login to view comments. Click here to Login
Biologic Therapies Summit IX, 2021
29:06
Cleveland Clinic Rheumatology

Vaccines for IMIDS: State of the Art

Feat. C. Calabrese
32:34
Cleveland Clinic Rheumatology

Advances in Pulmonary Aspects of Progressive Systemic Sclerosis

Feat. K. Highland
27:37
Cleveland Clinic Rheumatology

Targeted Theories in irAES

Feat. K. Esfahani
21:36
Cleveland Clinic Rheumatology

Safety of Biologics and JAK Inhibitors (Mycobacterial Infections)

Feat. K. Winthrop
20:09
Cleveland Clinic Rheumatology

ANCA and Endocarditis

Feat. A. Brown
40:36
Cleveland Clinic Rheumatology

Taking a Closer Look at RA Treatments With a Focus on JAKi: New drug…

Feat. S. Cohen
43:51
Cleveland Clinic Rheumatology

What do we Really Know About Non-Radiographic Spondyloarthropathy?

Feat. M. Magrey
09:25
Cleveland Clinic Rheumatology

What's New in PsA: Case Presentation

Feat. J. Yedimenko
07:07
Cleveland Clinic Rheumatology

What’s New in RA: Case Presentation

Feat. E. Littlejohn
09:59
Cleveland Clinic Rheumatology

What’s New in SpA: Case Presentation

Feat. S. Keller
33:23
Cleveland Clinic Rheumatology

Evolving Treatment Strategies in PsA: How do we Choose?

Feat. A. Kavanaugh
26:31
Cleveland Clinic Rheumatology

Clinical Approach to Diagnosis and Treatment of Cytokine Storm in Rh…

Feat. R. Q. Cron
29:14
Cleveland Clinic Rheumatology

Cytokine Storm: Where Rheumatologists, Oncologists, and ID Meet

Feat. D. Fajgenbaum
32:56
Cleveland Clinic Rheumatology

COVID-19 and Autoimmunity

Feat. P. Utz
35:13
Cleveland Clinic Rheumatology

COVID-19: What Have we Learned in One Year?

Feat. L. Calabrese
21:21
Cleveland Clinic Rheumatology

What Have Registries Taught Us?

Feat. J. Yazdany
24:22
Cleveland Clinic Rheumatology

Does Plasma Exchange Have a Role in Patients With ANCA-Associated Va…

Feat. M. Walsh
20:03
Cleveland Clinic Rheumatology

What Dose and Duration of Glucocorticoids Should be Used in ANCA-Ass…

Feat. P. Merkel
16:17
Cleveland Clinic Rheumatology

A Vasculitis Case Presentation

Feat. C. Gota
15:04
Cleveland Clinic Rheumatology

Vasculitis Treatment Case Presentation

Feat. A. Brown
20:17
Cleveland Clinic Rheumatology

When Should Biologic Agents be Considered in Eosinophilic Granulomat…

Feat. M. Wechsler
19:31
Cleveland Clinic Rheumatology

Are There Factors That Can Guide Treatment Decisions in Newly Diagno…

Feat. A. Villa-Forte
25:36
Cleveland Clinic Rheumatology

When Should Biologic Agents be Introduced in Giant Cell Arteritis an…

Feat. K. Warrington
17:58
Cleveland Clinic Rheumatology

What Are the Options for Treating CNS Vasculitis?

Feat. R. Hajj-Ali
21:20
Cleveland Clinic Rheumatology

How do I Recognize and Treat the VEXAS Syndrome?

Feat. P. Grayson
21:33
Cleveland Clinic Rheumatology

Is There Still a Role for Conventional Immunosuppressive Agents in A…

Feat. C. Langford
23:51
Cleveland Clinic Rheumatology

Maintenance Rituximab in ANCA-Associated Vasculitis: Dose, Frequency…

Feat. R. Smith
21:40
Cleveland Clinic Rheumatology

How Does the Treatment of Behçet’s Disease Differ Based on Disease M…

Feat. G. Hatemi